MalariaDRIPICCONCT01936766
Optimal Fluid Management in Adult Severe Malaria
An observational study of Malaria and Sepsis, run by University of Oxford at 1 site in Bangladesh.
Trial summary
Optimal fluid therapy in severe falciparum malaria has not been well defined, especially in resource poor settings where access to mechanical ventilation is limited. Recent studies suggest that liberal fluid resuscitation is harmful for severe malaria patients despite they often being hypovolemic on admission. Read more about this study
- Who is it for?
- Ages 16 to 65 years
- How many people
- 156 participants
- Where
- 1 siteBangladesh
- Study dates
- May 2013to Dec 2017
- How long will I take part?
- 14 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with severe malaria or severe sepsis admitted to the secondary or tertiary care center
Who may be able to join
- Severe Malaria
- Any level of asexual form of P. falciparum parasitemia on blood smear
- Severe malaria with one or more of the following:
- Cerebral malaria (GCS < 11). ii. Renal impairment (Creatinine > 2mg/dL or Anuria) iii. Hypoglycaemia (Glucose < 40mg/dL) iv. Systolic blood pressure < 80mmHg with cool extremities v. Pulmonary edema vi. Venous bicarbonate < 15mmol/L vii. Venous lactate > 4mmol/L
- Age 16-65 years
- Written informed consent obtained from patient or attending relative.
Show all 14Show fewer
- Severe Sepsis
- Negative blood smear for any Plasmodium species
- Clinical signs of infection with two of following:
- Heart rate > 90/min ii. Respiratory rate > 20/min iii. Body temperature >38°C or <36°C iv. White blood cell count of > 12000/μL or < 4000/μL
- Severe sepsis with one or more of the following due to infection:
- Systolic blood pressure < 90mmHg despite fluid resuscitation ii. Lactate > 4mmol/L iii. Urine output < 0.5mL/kg/hour for > 2 hours despite fluid resuscitation iv. Acute lung injury with PaO2/FiO2 < 250 in the absence of pneumonia v. Acute lung injury with PaO2/FiO2 < 200 in the presence of pneumonia vi. Creatinine > 2mg/dL vii. Bilirubin > 2mg/dL viii. Platelet count < 100000/μL
- Age 16-65 years
- Written informed consent obtained from patient or attending relative
Who cannot join
- Severe Malaria
- Patient or relative unable or unwilling to give informed consent
- Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
- Spontaneous bleeding or platelet count < 30000/μL on enrollment
- Pregnancy.
- Contraindication or unsuitable condition for thermodilution technique
Show all 12Show fewer
- Severe Sepsis
- Patient or relative unable or unwilling to give informed consent
- Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
- Spontaneous bleeding or platelet count < 30000/μL on enrollment
- Pregnancy.
- Contraindication or unsuitable condition for thermodilution technique
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy
Optimal fluid therapy in severe falciparum malaria has not been well defined, especially in resource poor settings where access to mechanical ventilation is limited. Recent studies suggest that liberal fluid resuscitation is harmful for severe malaria patients despite they often being hypovolemic on admission. In order to elucidate the minimum fluid therapy required to prevent complications in severe malaria, we will conduct a prospective observational study in adults with severe malaria, and also in adults with severe sepsis as a comparison group. The objective of this study is to describe the association between hemodynamic variations in conventional fluid management and the probability of developing acute kidney injury (AKI) or pulmonary edema in adults with severe malaria and severe sepsis. Hemodynamic measurements will be obtained by using transpulmonary thermodilution and arterial pulse contour analysis.
Read the detailed description
Background
Fluid therapy in severe malaria and severe sepsis.
Severe falciparum malaria causes multiple organ dysfunction including metabolic acidosis, coma, anemia, acute kidney injury (AKI), and pulmonary edema. The mortality rate of the disease is still around 15-23% despite optimal antimalarial therapy. Supportive therapy and intensive care are crucial elements in the treatment of the multiple complications of the disease. Optimal fluid therapy however, one of the fundamental elements of the supportive therapy, has not been well defined. A large randomized controlled trial of fluid therapy in shocked African children (the FEAST study) showed that fluid bolus resuscitation increased the mortality in severe malaria. A retrospective study in adult patients with severe malaria showed that fluid loading had no effect on acid-base status or renal failure. A recent study by our group showed that liberal fluid management guided by invasive monitoring was not associated with improved renal function or acid-base status, but did aggravate pulmonary edema in patients developing pulmonary capillary leakage during admission in the intensive care unit. The study found that 38% of severe malaria patients developed clinical pulmonary edema, 80% of which occurred after liberal fluid resuscitation. In this study, plasma lactate as a crude measure of tissue hypoperfusion correlated with the degree of sequestration (directly observed by OPS imaging), and not with the volume of fluid resuscitation. It was concluded that liberal fluid management is not indicated in adult severe malaria. However, this same study showed that all patients with severe malaria present with intravascular dehydration, and often have not been able to maintain proper fluid intake for a considerable time. Failure to give these patients enough fluid therapy could therefore be expected to precipitate renal failure and tissue hypoperfusion. Overall, the evidence suggests that in severe malaria, liberal fluid resuscitation is harmful despite patients often being hypovolaemic on admission. The minimum fluid therapy required to prevent complications has yet to be defined. Currently, the clinician has no guidance except for the very general adage: "keep them dry".
Evidence for fluid therapy in sepsis and septic shock is also limited. Goal-directed resuscitation during the first 6 hours is recommended by the Surviving Sepsis Campaign Guideline (SSCG), based on two randomized controlled study. Fluid challenges are one of the methods used to achieve the goals, with administration of fluid boluses and initial higher volume of intravenous fluids. Due to its inclusion in guidelines1, early goal-directed therapy (EGDT) and fluid challenges have now become common clinical practice in resource-rich countries. On the other hand, the efficacy of large fluid bolus resuscitation is questioned because of low level of evidence for physiological support and lack of clinical controlled trials comparing fluid bolus therapy versus no fluid bolus therapy. The variable availability of mechanical ventilation must be considered when making recommendations for fluid resuscitation. Since access to mechanical ventilation is often limited in developing world settings, the recommendations in the SSCG are not applicable in this context without additional evaluation. Recently, the FEAST trial in East African children with compensated shock in severe malaria and sepsis revealed that fluid bolus therapy of 20 to 40 mL/kg body weight caused a dramatic increase in case fatality. Several studies have found positive fluid balance to be associated with increased mortality in sepsis or septic shock. A retrospective study (the VASST study) included 778 patients with septic shock showed that there is significant correlation between a more positive fluid balance at both time points of 12 hours and day 4 and increased mortality. In the SOAP study, multicenter prospective cohort study enrolled 1177 patients with sepsis, cumulative fluid balance within first 72 hours after the onset was an independent predictor of mortality. Also, a prospective observational study of 164 patients with septic shock reported that there was no significant difference in 90-days mortality between patients with higher fluid volume infused (> 4.0 L) and lower volume (< 4.0 L) on day 1. They concluded that initial fluid volume administered was not associated with mortality in patients with septic shock. Optimal initial fluid volume and strategy in sepsis and septic shock is thus unclear. Especially in resource-limited countries, fluid overload is more dangerous than that in resource-rich countries, because development of pulmonary edema and ALI/ARDS is almost always fatal in settings without access to mechanical ventilation. The recommendation of fluid bolus resuscitation therapy as promoted in the SSCG should therefore be evaluated cautiously in the resource-poor setting.
Rationale
As outlined above, the optimum fluid management in severe malaria and sepsis has yet to be established, particularly in resource poor settings where access to mechanical ventilation is limited. Whilst liberal fluid resuscitation appears deleterious, it is not clear what the minimum fluid requirements are; this study aims to address this question.
Procedures
The investigators will longitudinally monitor the hemodynamic parameters along with cumulative fluid administration and fluid balance during conventional fluid strategy, as practiced by the local physicians. For monitoring, we will use transpulmonary thermodilution and arterial pulse contour analysis (PiCCO-plus, Pulsion Medical System, Germany). The PiCCO system is in routine use as part of standard clinical practice to provide hemodynamic monitoring of severely ill patients admitted to ICU. It uses a central venous and arterial line to provide continuous monitoring of hemodynamic function.
Overall, the investigators believe that by monitoring the hemodynamics using the PiCCO system will give valuable new insight into the relationship between fluid management and renal function, pulmonary edema, and acid-base status in adult patients with severe malaria. Patients with severe sepsis will be recruited as a comparison group, and the volume status will be evaluated in the same manner.
- Keywords
- malaria, falciparum, sepsis, fluid therapy, thermodilution, extravascular lung water, acute kidney injury
- Medical subject headings
- Malaria, Sepsis, Malaria, Falciparum, Acute Kidney Injury
What is being measured
The primary outcome is the main question the study is designed to answer.
Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index
The association between the mean Global End-Diastolic Volume Index (GEDVI) over the first 24 hours and (1) serum creatinine level, and (2) Extravascular Lung Water Index (EVLWI)
Measured: 24 hours
Secondary outcomes (11)
Association between the GEDVI,after conventional fluid resuscitation, and (1) serum creatinine level, (2) EVLWI
The association between the GEDVI at 6, 12, 18 or 24 hours after conventional fluid resuscitation and (1) serum creatinine level, (2) EVLWI
Measured: 24 hours
Correlation between GEDVI and changes over time in plasma lactate level
Measured: 72 hours
Change in central venous oxygen saturation (ScvO2) in relation to GEDVI and its association with acid-base status
Measured: 72 hours
Incidence of pulmonary edema and ALI/ARDS
Incidence of pulmonary edema defined by increase of EVLWI (≥ 10 mL/kg) and ALI/ARDS in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid administration
Measured: 72 hours
Incidence of AKI and induction rate of renal replacement therapy
Incidence of AKI defined by RIFLE or AKIN criteria and induction rate of renal replacement therapy in relation to proportion of blocked capillaries (observed by OPS), GEDVI and cumulative fluid balance
Measured: 72 hours
Time course of hemodynamic parameters in relation to fluid therapy
Time course of hemodynamic parameters, i.e. Cardiac Index (CI), Global Ejection Fraction (GEF), Stroke Volume Variation (SVV) in relation to fluid therapy
Measured: 72 hours
Time course of respiratory parameters in relation to fluid therapy
Time course of respiratory parameters, i.e. PaO2/FiO2 ratio, Pulmonary Vascular Permeability Index (PVPI) in relation to fluid therapy
Measured: 72 hours
Parasite burden in adults with severe malaria in relation to organ damage (renal, pulmonary)
Parasite burden, i.e. PfHRP2, peripheral blood parasitemia, parasite staging at enrollment in adults with severe malaria in relation to organ damage (renal, pulmonary)
Measured: 72 hours
Evaluation of Biomarkers for early detection of ARDS
Evaluation of Biomarkers for early detection of ARDS in both severe malaria and sepsis (plasma transferrin, albumin, others)
Measured: 72 hours
Correlation between GEDVI and clinical variables
Correlation between GEDVI and clinical variables including the jugular venous pressure (JVP) as a measure of volume status or passive leg raising as an indicator of fluid responsiveness
Measured: 72 hours
Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis
Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis, based on the optimal GEDVI defined by primary outcome measures and secondary outcome measures No. 1
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Sep 2013 (estimated)
- Study startMay 2013
- Primary completionDec 2017
- Study completionDec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MalariaStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 156 participants (actual)
- Target duration
- 14 Days
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Arjen Dondorp, MD, Principal investigator, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01936766
- Sponsor's protocol ID
- BAKMAL 1302
- Acronym
- DRIPICCO
- Status last verified
- Aug 2018
- First submitted
- 27 Aug 2013
- Last updated
- 16 Aug 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy
- ClinicalTrials.gov ID
- NCT01936766
- Acronym / sponsor ID
- DRIPICCO / BAKMAL 1302
- Keywords
- malaria, falciparum, sepsis, fluid therapy, thermodilution, extravascular lung water, acute kidney injury
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 156 participants (actual)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Study start
- May 2013 (actual)
- Primary completion
- Dec 2017 (actual)
- Study completion
- Dec 2017 (actual)
- First posted
- 6 Sep 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Optimal fluid therapy in severe falciparum malaria has not been well defined, especially in resource poor settings where access to mechanical ventilation is limited. Recent studies suggest that liberal fluid resuscitation is harmful for severe malaria patients despite they often being hypovolemic on admission. In order to elucidate the minimum fluid therapy required to prevent complications in severe malaria, we will conduct a prospective observational study in adults with severe malaria, and also in adults with severe sepsis as a comparison group. The objective of this study is to describe the association between hemodynamic variations in conventional fluid management and the probability of developing acute kidney injury (AKI) or pulmonary edema in adults with severe malaria and severe sepsis. Hemodynamic measurements will be obtained by using transpulmonary thermodilution and arterial pulse contour analysis.
Detailed description
Background
Fluid therapy in severe malaria and severe sepsis.
Severe falciparum malaria causes multiple organ dysfunction including metabolic acidosis, coma, anemia, acute kidney injury (AKI), and pulmonary edema. The mortality rate of the disease is still around 15-23% despite optimal antimalarial therapy. Supportive therapy and intensive care are crucial elements in the treatment of the multiple complications of the disease. Optimal fluid therapy however, one of the fundamental elements of the supportive therapy, has not been well defined. A large randomized controlled trial of fluid therapy in shocked African children (the FEAST study) showed that fluid bolus resuscitation increased the mortality in severe malaria. A retrospective study in adult patients with severe malaria showed that fluid loading had no effect on acid-base status or renal failure. A recent study by our group showed that liberal fluid management guided by invasive monitoring was not associated with improved renal function or acid-base status, but did aggravate pulmonary edema in patients developing pulmonary capillary leakage during admission in the intensive care unit. The study found that 38% of severe malaria patients developed clinical pulmonary edema, 80% of which occurred after liberal fluid resuscitation. In this study, plasma lactate as a crude measure of tissue hypoperfusion correlated with the degree of sequestration (directly observed by OPS imaging), and not with the volume of fluid resuscitation. It was concluded that liberal fluid management is not indicated in adult severe malaria. However, this same study showed that all patients with severe malaria present with intravascular dehydration, and often have not been able to maintain proper fluid intake for a considerable time. Failure to give these patients enough fluid therapy could therefore be expected to precipitate renal failure and tissue hypoperfusion. Overall, the evidence suggests that in severe malaria, liberal fluid resuscitation is harmful despite patients often being hypovolaemic on admission. The minimum fluid therapy required to prevent complications has yet to be defined. Currently, the clinician has no guidance except for the very general adage: "keep them dry".
Evidence for fluid therapy in sepsis and septic shock is also limited. Goal-directed resuscitation during the first 6 hours is recommended by the Surviving Sepsis Campaign Guideline (SSCG), based on two randomized controlled study. Fluid challenges are one of the methods used to achieve the goals, with administration of fluid boluses and initial higher volume of intravenous fluids. Due to its inclusion in guidelines1, early goal-directed therapy (EGDT) and fluid challenges have now become common clinical practice in resource-rich countries. On the other hand, the efficacy of large fluid bolus resuscitation is questioned because of low level of evidence for physiological support and lack of clinical controlled trials comparing fluid bolus therapy versus no fluid bolus therapy. The variable availability of mechanical ventilation must be considered when making recommendations for fluid resuscitation. Since access to mechanical ventilation is often limited in developing world settings, the recommendations in the SSCG are not applicable in this context without additional evaluation. Recently, the FEAST trial in East African children with compensated shock in severe malaria and sepsis revealed that fluid bolus therapy of 20 to 40 mL/kg body weight caused a dramatic increase in case fatality. Several studies have found positive fluid balance to be associated with increased mortality in sepsis or septic shock. A retrospective study (the VASST study) included 778 patients with septic shock showed that there is significant correlation between a more positive fluid balance at both time points of 12 hours and day 4 and increased mortality. In the SOAP study, multicenter prospective cohort study enrolled 1177 patients with sepsis, cumulative fluid balance within first 72 hours after the onset was an independent predictor of mortality. Also, a prospective observational study of 164 patients with septic shock reported that there was no significant difference in 90-days mortality between patients with higher fluid volume infused (> 4.0 L) and lower volume (< 4.0 L) on day 1. They concluded that initial fluid volume administered was not associated with mortality in patients with septic shock. Optimal initial fluid volume and strategy in sepsis and septic shock is thus unclear. Especially in resource-limited countries, fluid overload is more dangerous than that in resource-rich countries, because development of pulmonary edema and ALI/ARDS is almost always fatal in settings without access to mechanical ventilation. The recommendation of fluid bolus resuscitation therapy as promoted in the SSCG should therefore be evaluated cautiously in the resource-poor setting.
Rationale
As outlined above, the optimum fluid management in severe malaria and sepsis has yet to be established, particularly in resource poor settings where access to mechanical ventilation is limited. Whilst liberal fluid resuscitation appears deleterious, it is not clear what the minimum fluid requirements are; this study aims to address this question.
Procedures
The investigators will longitudinally monitor the hemodynamic parameters along with cumulative fluid administration and fluid balance during conventional fluid strategy, as practiced by the local physicians. For monitoring, we will use transpulmonary thermodilution and arterial pulse contour analysis (PiCCO-plus, Pulsion Medical System, Germany). The PiCCO system is in routine use as part of standard clinical practice to provide hemodynamic monitoring of severely ill patients admitted to ICU. It uses a central venous and arterial line to provide continuous monitoring of hemodynamic function.
Overall, the investigators believe that by monitoring the hemodynamics using the PiCCO system will give valuable new insight into the relationship between fluid management and renal function, pulmonary edema, and acid-base status in adult patients with severe malaria. Patients with severe sepsis will be recruited as a comparison group, and the volume status will be evaluated in the same manner.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 14 Days
Who may qualify
- Ages
- 16 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with severe malaria or severe sepsis admitted to the secondary or tertiary care center
Key inclusion criteria (14 listed)
- Severe Malaria
- Any level of asexual form of P. falciparum parasitemia on blood smear
- Severe malaria with one or more of the following:
- Age 16-65 years
- Written informed consent obtained from patient or attending relative.
Key exclusion criteria (12 listed)
- Severe Malaria
- Patient or relative unable or unwilling to give informed consent
- Serious pre-existing disease The following exclusion criteria described below are applied to patient for whom invasive hemodynamic monitoring will be performed.
- Spontaneous bleeding or platelet count < 30000/μL on enrollment
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index
Time frame: 24 hours
The association between the mean Global End-Diastolic Volume Index (GEDVI) over the first 24 hours and (1) serum creatinine level, and (2) Extravascular Lung Water Index (EVLWI)
11 secondary outcomes
Association between the GEDVI,after conventional fluid resuscitation, and (1) serum creatinine level, (2) EVLWI
Time frame: 24 hours
Correlation between GEDVI and changes over time in plasma lactate level
Time frame: 72 hours
Change in central venous oxygen saturation (ScvO2) in relation to GEDVI and its association with acid-base status
Time frame: 72 hours
Incidence of pulmonary edema and ALI/ARDS
Time frame: 72 hours
Incidence of AKI and induction rate of renal replacement therapy
Time frame: 72 hours
Time course of hemodynamic parameters in relation to fluid therapy
Time frame: 72 hours
Time course of respiratory parameters in relation to fluid therapy
Time frame: 72 hours
Parasite burden in adults with severe malaria in relation to organ damage (renal, pulmonary)
Time frame: 72 hours
Evaluation of Biomarkers for early detection of ARDS
Time frame: 72 hours
Correlation between GEDVI and clinical variables
Time frame: 72 hours
Evaluation of the fluid requirements for resuscitation in patients with severe malaria or sepsis
Time frame: 72 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Aug 2018.
Related trials for Malaria
Active, not recruitingObservational study
Trajectories and Mechanisms of Recovery From Malaria: An Observational Study
Malaria
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Recruiting
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Iron Deficiencies
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arjen Dondorp, MD principal investigator
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malaria and Sepsis, run by University of Oxford at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2018.